Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

LL-37 and Sermorelin Interaction: Synergistic | Peptide Database

Compound Profiles LL-37 Human Cathelicidin | Antimicrobial Peptide Provides direct antimicrobial activity through membrane disruption, promotes wound healing by enhancing keratinocyte migration and angiogenesis, and modulates immune responses without systemic

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

LL-37

Human Cathelicidin | Antimicrobial Peptide

Provides direct antimicrobial activity through membrane disruption, promotes wound healing by enhancing keratinocyte migration and angiogenesis, and modulates immune responses without systemic exposure when used topically..

Sermorelin

GHRH Analog | Growth Hormone Releasing Hormone

Subcutaneous injection provides optimal bioavailability for binding GHRH receptors, stimulating pulsatile GH release while maintaining hypothalamic-pituitary axis integrity and allowing natural somatostatin negative feedback..

Combined Organ Load

Frequently Asked Questions

Can I take LL-37 with Sermorelin?

Yes, LL-37 and Sermorelin can generally be taken together. LL-37 and Sermorelin work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.

Is LL-37 and Sermorelin safe together?

Based on pharmacological analysis, this combination is considered synergistic. No critical safety flags identified for this pair.

What are the interactions between LL-37 and Sermorelin?

LL-37 and Sermorelin work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols. This assessment has 47% confidence and is inferred from pharmacological mechanism analysis.

How should I time LL-37 and Sermorelin?

LL-37 has a half-life of Short (rapid proteolytic degradation) and Sermorelin has a half-life of 10-12 minutes. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Community Research

Join others researching PE-22-28 — share findings, ask questions, and learn from real experiences Synthetic heptapeptide derived from Spadin positions 22-28, functioning as potent TREK-1 antagonist with enhanced selectivity and duration versus parent compound. Primary research focus on rapid antidepressant effects. Selectively blocks TREK-1 potassium channels (IC50: 0.12 nM). Enhances serotonin neurotransmission in dorsal raphe nucleus, triggering CREB activation and hippocampal neurogenesis.

Source: peptide-db.com ↗

Research Indications

Raloxifene is considered the most effective SERM for reversing existing gynecomastia. Its strong antagonism at breast tissue estrogen receptors directly blocks the estradiol signaling that drives glandular proliferation. Clinical and anecdotal evidence consistently favors raloxifene over tamoxifen for reducing established gynecomastia tissue. Blocks estrogen receptor activation in breast tissue during aromatizable steroid cycles without reducing systemic estrogen levels. Preferred over tamoxifen when the primary goal is gynecomastia prevention rather than HPTA stimulation. FDA-approved for prevention and treatment of postmenopausal osteoporosis. Raloxifene acts as an estrogen agonist in bone tissue, maintaining bone mineral density and reducing the risk of vertebral fractures. The MORE trial demonstrated a 30-50% reduction in vertebral fracture risk. FDA-approved for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk of breast cancer. The STAR trial demonstrated equivalent efficacy to tamoxifen for invasive breast cancer risk reduction with fewer side effects.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Subcutaneous administration optimal for bioavailability; available as blended vials or separate formulations. General Health Optimization 200mcg each (0.2mL if 1mg/mL) Once daily SubQ Performance Enhancement 250mcg each (0.25mL if 1mg/mL) Recovery Optimization 300mcg each (0.3mL if 1mg/mL) Conservative Approach 150mcg each (0.15mL if 1mg/mL) 5 days per week

Source: peptide-db.com ↗
Side effects

Common Side Effects

Scalp irritation, dryness, or flaking (topical, especially solution formulations containing propylene glycol) Initial shedding phase during the first 1-3 months of treatment Hypertrichosis (unwanted facial and body hair growth, more common with oral administration) Fluid retention and mild peripheral edema (oral) Mild dizziness or lightheadedness upon standing (oral, due to vasodilation)

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides